NANJING, China, May 22 /PRNewswire-FirstCall/ -- China Biopharmaceuticals Holdings, Inc. ("CBH") , a leading Chinese pharmaceutical company focused on the development, manufacturing and distribution of innovative drugs in China, recently announced results for the three months ended March 31, 2006, the details of which can be found in its Form 10QSB, which has been filed with the US Securities and Exchange Commission.
On Wednesday, May 24, 2006 Chris Peng Mao, CEO and Floyd Huang, CFO will host a conference call at 10:00 AM (Eastern) to discuss first quarter results and the recent agreement to acquire 100% interest in Shenyang Enshi Pharmaceutical, a leading manufacturer and distributor of pharmaceutical products in China. Interested parties can access the call by dialing in toll free (866) 850-2201 / (718) 354-1362 (US) or 0800 279 9640 / +44-207-138-0838 (International). A telephone replay will be available shortly after the call. The telephone replay number is (718) 354-1112 (US) or +44(0)20 7806 1970 (International); Passcode: 6823947. This conference call will last forty-five minutes.
About China Biopharmaceuticals Holdings
China Biopharmaceuticals Holdings, Inc. (CBH) is a research driven pharmaceutical company dedicated to the discovery, development, manufacturing and marketing of small and large molecule pharmaceutical products including medicines, vaccines, and active pharmaceutical ingredients for various categories of diseases. CBH is a US public company with operating subsidiaries and senior management based in China.
For further information, please visit our website at http://www.cbioinc.com. CONTACT: Chris Peng Mao, CEO 86-25-8320-5758 cmao@cbioinc.com Mahmoud Siddig 212-889-4350 mahmoud.siddig@taylor-rafferty.com
China Biopharmaceuticals Holdings, Inc.
CONTACT: Chris Peng Mao, CEO, +86-25-8320-5758, cmao@cbioinc.com; orMahmoud Siddig, +1-212-889-4350, mahmoud.siddig@taylor-rafferty.com, forChina Biopharmaceuticals Holdings, Inc.
Web site: http://www.cbioinc.com/
